利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.072 秒)

    Compounds
    23.
    发明授权
    Compounds 有权
    化合物

    公开(公告)号：US06369224B1

    公开(公告)日：2002-04-09

    申请号：US09594703

    申请日：2000-06-16

    申请人： Eifion Phillips ,  Robert Mack ,  John Macor ,  Simon Semus

    发明人： Eifion Phillips ,  Robert Mack ,  John Macor ,  Simon Semus

    IPC分类号： C07F502

    CPC分类号： C07D491/22

    摘要： A compound of formula wherein n is 0 or 1; m is 0 or 1; p is 0 or 1; X is oxygen or sulfur; Y is CH, N or NO; W is oxygen, H2 or F2; A is N or C(R2); G is N or C(R3); D is N or C(R4); with the proviso that no more than one of A, G, and D is nitrogen, but at least one of Y, A, G, and D is nitrogen or NO; R1 is hydrogen or C1 to C4 alkyl; R2, R3, and R4 are independently hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, OH, OC1-C4 alkyl, CO2R1, —CN, —NO2, —NR5R6, —CF3, —OSO2CF3 or R2 and R3, or R3 and R4, respectively, may together form another six membered aromatic or heteroaromatic ring sharing A and G, or G and D, respectively, containing between zero and two nitrogen atoms, and substituted with one to two of the following substituents: independently hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, OH, OC1-C4 alkyl, CO2R1, —CN, —NO2, —NR5R6, —CF3, —OSO2CF3; R5 and R6 are independently hydrogen, C1-C4 alkyl, C(O)R7, C(O)NHR8, C(O)OR9, SO2R10 or may together be (CH2)jQ(CH2)k where Q is O, S, NR11, or a bond; j is 2 to 7, k is 0 to 2; R7, R8, R9, R10, and R11 are independently C1-C4 alkyl, aryl, or heteroaryl, or an enantiomer thereof, and the pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.

    摘要翻译： 化学式为0或1; m为0或1; p为0或1; X是氧或硫; Y是CH，N或NO; W是氧，H 2或F 2; A是N或C（R 2）; G为N或C（R3）; D是N或C（R4）;条件是A，G和D中不超过一个是氮，但Y，A，G和D中的至少一个是氮或NO; R 1是氢或C 1 至C 4烷基; R 2，R 3和R 4独立地是氢，卤素，C 1 -C 4烷基，C 2 -C 4烯基，C 2 -C 4炔基，芳基，杂芳基，OH，OC 1 -C 4烷基，CO 2 R 1，-CN，-NO 2， -NR5R6，-CF3，-OSO2CF3或R2和R3或R3和R4分别可以共同形成分别含有0和2个氮原子之间的分别为A和G或G和D的六元芳族或杂芳族环， 并被一至两个以下取代基取代：独立地是氢，卤素，C 1 -C 4烷基，C 2 -C 4烯基，C 2 -C 4炔基，芳基，杂芳基，OH，OC 1 -C 4烷基，CO 2 R 1，-CN，-NO 2， -NR5R6，-CF3，-OSO2CF3; R 5和R 6独立地是氢，C 1 -C 4烷基，C（O）R 7，C（O）NHR 8，C（O）OR 9，SO 2 R 10或可以一起为（CH 2）j Q（CH 2） NR11，或债券; j为2〜7，k为0〜2; R 7，R 8，R 9，R 10和R 11独立地为C 1 -C 4烷基，芳基或杂芳基，或其对映体及其药学上可接受的盐，其制备方法，含有它们的组合物及其在治疗中的用途， 在治疗或预防精神病和智力障碍。

    Oxazolidinone nicotinic acetylcholine receptor agonists
    25.
    发明授权
    Oxazolidinone nicotinic acetylcholine receptor agonists 失效
    恶唑烷酮烟碱乙酰胆碱受体激动剂

    公开(公告)号：US07514567B2

    公开(公告)日：2009-04-07

    申请号：US10563271

    申请日：2004-07-06

    申请人： Hui-Fang Chang ,  Eifion Phillips

    发明人： Hui-Fang Chang ,  Eifion Phillips

    IPC分类号： A61K31/421 ,  A61K31/422 ,  A61K31/424 ,  C07D413/02 ,  C07D498/10

    CPC分类号： C07D498/20

    摘要： Compounds of formula I: and pharmaceutically-acceptable salts thereof, wherein Q, Ar1, A and Ar2 are as defined in the specification, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them, uses of them as medicaments for therapy, uses of them in the manufacture of medicaments and uses of them for diagnostic and analytic purposes.

    摘要翻译： 式I化合物及其药学上可接受的盐，其中Q，Ar1，A和Ar2如说明书中所定义，药物组合物和含有它们的制剂，使用它们单独或与其它组合一起治疗疾病和病症的方法 用于制备它们的治疗活性化合物或物质，方法和中间体，它们作为治疗药物的用途，它们在制备药物中的用途以及它们用于诊断和分析目的的用途。

    Spiroazabicyclic heterocyclic compounds
    26.
    发明授权
    Spiroazabicyclic heterocyclic compounds 失效
    螺环双环杂环化合物

    公开(公告)号：US07507744B2

    公开(公告)日：2009-03-24

    申请号：US10801085

    申请日：2004-03-15

    申请人： Eifion Phillips ,  Robert Mack ,  John Macor ,  Simon Semus

    发明人： Eifion Phillips ,  Robert Mack ,  John Macor ,  Simon Semus

    IPC分类号： A61K31/4747 ,  C07D221/20

    CPC分类号： C07D491/22

    摘要： A pharmaceutical composition comprising a compound of formula wherein n, m, p, X, Y, W, A, G and D are as defined in the specification, enantiomers thereof, or pharmaceutically acceptable salts thereof, its use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.

    摘要翻译： 一种药物组合物，其包含下式化合物其中n，m，p，X，Y，W，A，G和D如说明书中所定义，其对映体或其药学上可接受的盐，其用于治疗， 治疗或预防精神病和智力障碍。

    Heterocyclic compounds
    27.
    发明授权
    Heterocyclic compounds 失效
    杂环化合物

    公开(公告)号：US07417050B2

    公开(公告)日：2008-08-26

    申请号：US10511525

    申请日：2003-04-15

    申请人： Hui-Fang Chang ,  Eifion Phillips

    发明人： Hui-Fang Chang ,  Eifion Phillips

    IPC分类号： A61K31/44 ,  C07D401/04

    CPC分类号： C07D491/22

    摘要： Compounds of formula I: and pharmaceutically-acceptable salts thereof, wherein Ar and R are as defined in the specification, compositions containing such compounds and the use of such compounds and compositions for use in therapy.

    摘要翻译： 式I化合物及其药学上可接受的盐，其中Ar和R如说明书中所定义，含有这些化合物的组合物以及用于治疗的这些化合物和组合物的用途。

    Furyl compounds
    28.
    发明授权
    Furyl compounds 失效
    呋喃基化合物

    公开(公告)号：US07417049B2

    公开(公告)日：2008-08-26

    申请号：US10511535

    申请日：2003-04-15

    申请人： Hui-Fang Chang ,  Yan Li ,  Eifion Phillips

    发明人： Hui-Fang Chang ,  Yan Li ,  Eifion Phillips

    IPC分类号： C07D401/04 ,  C07D401/14 ,  A61K43/08

    CPC分类号： C07D491/22

    摘要： Compounds of formula I: and pharmaceutically-acceptable salts thereof, wherein Ar and R are as defined in the specification, compositions containing such compounds and methods of using such compounds and compositions in therapy.

    摘要翻译： 式I化合物及其药学上可接受的盐，其中Ar和R如说明书中所定义，含有这些化合物的组合物以及在治疗中使用这些化合物和组合物的方法。